Abstract 293P
Background
This study examines the incidence of chemotherapy side effects in Moroccan women with localized breast cancer (BC) undergoing anthracycline and taxane-containing regimens. Furthermore, we introduce a new initiative in the form of an AI mobile health app designed for remote monitoring and support during chemotherapy.
Methods
A structured questionnaire was used to gather information from 122 participants at the hospital's outpatient Department regarding their experiences with chemotherapy side effects. The incidence and relative risk of side effects were compared using a chi-square test. Additionally, an AI mobile health app was developed in two phases. During Phase A, a multidisciplinary expert group collaborated to develop the tool using a dataset. Currently, Phase B is ongoing and focuses on assessing the predictive accuracy of the tool using prospective data from BC patients undergoing chemotherapy.
Results
Anthracycline-based regimens were found to have a higher prevalence of side effects, including asthenia, vomiting, nausea, constipation, mucositis, and appetite loss. Taxane-containing regimens were associated with an increased incidence of allergies, edema, neuropathy, arthromyalgia, and ocular toxicity. The relative risk analysis showed significantly higher risks for vomiting, nausea, appetite loss, asthenia, mucositis, nail toxicity, and constipation with anthracyclines compared to taxanes. The AI mobile health app enables patients to report side effects, access health information, and receive self-help advice. Physicians can remotely monitor patients and intervene based on symptom severity.
Conclusions
BC patients often face significant challenges due to the side effects of chemotherapy. Effective management strategies are necessary to address these challenges. An innovative solution for remote monitoring and support is the introduction of an AI mobile health app. This facilitates continuous care while minimizing the need for frequent in-person visits. This approach is particularly advantageous for patients in medically underserved areas or with limited mobility, emphasising a comprehensive and patient-centred approach to BC care.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.